Wehling M - Search Results

1

New anticoagulants - promising and failed developments.

Harenberg J, Marx S, Krejczy M, Wehling M. Harenberg J, et al. Among authors: wehling m. Br J Pharmacol. 2012 Jan;165(2):363-72. doi: 10.1111/j.1476-5381.2011.01578.x. Br J Pharmacol. 2012. PMID: 21740405 Free PMC article. Review.

2

Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

Harenberg J, Wehling M. Harenberg J, et al. Among authors: wehling m. Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023. Semin Thromb Hemost. 2008. PMID: 18393142 Review.

3

Future of anticoagulant therapy.

Harenberg J, Wehling M. Harenberg J, et al. Among authors: wehling m. Cardiovasc Ther. 2011 Oct;29(5):291-300. doi: 10.1111/j.1755-5922.2010.00198.x. Epub 2010 Jul 8. Cardiovasc Ther. 2011. PMID: 20626401 Free article. Review.

4

Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.

Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Harenberg J, et al. Among authors: wehling m. J Thromb Thrombolysis. 2011 Oct;32(3):267-71. doi: 10.1007/s11239-011-0622-5. J Thromb Thrombolysis. 2011. PMID: 21811937 Free PMC article.

5

Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

Harenberg J, Marx S, Dahl OE, Marder VJ, Schulze A, Wehling M, Weiss C. Harenberg J, et al. Among authors: wehling m. Thromb Haemost. 2012 Nov;108(5):903-12. doi: 10.1160/TH12-07-0482. Epub 2012 Sep 26. Thromb Haemost. 2012. PMID: 23014668

6

Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.

Du S, Harenberg J, Krämer S, Krämer R, Wehling M, Weiss C. Du S, et al. Among authors: wehling m. Ther Drug Monit. 2015 Jun;37(3):375-80. doi: 10.1097/FTD.0000000000000157. Ther Drug Monit. 2015. PMID: 25525760

7

Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants.

Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Harenberg J, et al. Among authors: wehling m. Semin Thromb Hemost. 2015 Mar;41(2):228-36. doi: 10.1055/s-0035-1544158. Epub 2015 Feb 15. Semin Thromb Hemost. 2015. PMID: 25682081 Free article. Review.

8

Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.

Krejczy M, Harenberg J, Marx S, Obermann K, Frölich L, Wehling M. Krejczy M, et al. Among authors: wehling m. J Thromb Thrombolysis. 2014 May;37(4):507-23. doi: 10.1007/s11239-013-0989-6. J Thromb Thrombolysis. 2014. PMID: 24221805

9

Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.

Zolfaghari S, Harenberg J, Froelich L, Wehling M, Weiss C. Zolfaghari S, et al. Among authors: wehling m. Semin Thromb Hemost. 2014 Feb;40(1):121-8. doi: 10.1055/s-0033-1361940. Epub 2013 Dec 31. Semin Thromb Hemost. 2014. PMID: 24381153 Free article. Clinical Trial.

10

Measurement of rivaroxaban and apixaban in serum samples of patients.

Harenberg J, Krämer S, Du S, Zolfaghari S, Schulze A, Krämer R, Weiss C, Wehling M, Lip GY. Harenberg J, et al. Among authors: wehling m. Eur J Clin Invest. 2014 Aug;44(8):743-52. doi: 10.1111/eci.12291. Eur J Clin Invest. 2014. PMID: 24931429 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

387 results

Search Page

Filters